Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vedolizumab - Takeda Oncology

Drug Profile

Vedolizumab - Takeda Oncology

Alternative Names: Entyvio; Kynteles; LDP-02; LPD-02; MLN-0002; MLN-002; MLN02

Latest Information Update: 04 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Medical College of Wisconsin; Millennium; Takeda; Takeda Oncology
  • Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Alpha4beta7 integrin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Crohn's disease; Ulcerative colitis
  • Phase II Coeliac disease; Graft-versus-host disease
  • Phase I Malignant melanoma

Most Recent Events

  • 01 Dec 2018 Adverse events data from a phase Ib trial in Graft-Versus-Host Disease​ presented at the 60th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2018)​
  • 07 Nov 2018 Launched for Ulcerative colitis in Japan (IV)
  • 22 Oct 2018 Efficacy and adverse events data from the phase III VISIBLE-1 trial in ulcerative colitis presented at the 26th United European Gastroenterology Week (UEG-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top